SIGA Technologies, Inc. SIGA R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.siga.com

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.

Market & Price

Market Cap

$335.67M

Current Price

$4.68

High / Low (52W)

$8.39 / $4.17

Beta

0.85

Valuation

Stock P/E

16.71

Industry PE

23.65

Forward P/E

4.46

PEG Ratio

3.37

Book Value

$2.78

Price to Book

1.69

P/S

3.58

EV/EBITDA

8.99

Dividend Yield

Profitability & Returns

ROCE

11.76%

ROE

11.00%

ROA

5.53%

Profit Margin

21.58%

Op Margin

-85.24%

EPS (Latest Qtr)

$-0.05

EPS (TTM)

$0.28

Balance Sheet & Liquidity

Debt/Equity

0.40

Quick Ratio

2.30

Current Ratio

3.25

Debt

$601.02K

Total Assets

$219.47M

Current Assets

$212.86M

Working Capital

$194.86M

Ownership

Promoter Holding

42.66%

Chg in Prom Hold

FII / Inst Holding

49.97%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$190.71M

Total Revenue (TTM)

$93.78M

EBITDA

$21.21M

Free Cash Flow

$59.44M

Operating Cash Flow

$27.75M

Shares Outstanding

71.72M

Gross Margin

43.56%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-5.13%

Profit 5Y

-11.78%

Revenue (YoY)

-11.30%

Earnings (YoY)

PROS

Excellent profit margin of 21.6%.
Generates positive free cash flow.

CONS

Revenue declined at -5.1% CAGR over 5 years.
Earnings shrank at -11.8% CAGR over 5 years.
Trading 44.2% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SIGA SIGA Technologies, Inc. R2K	4.68	16.71	$335.67M	-	11.76%	11.00%	-5.13%	-11.78%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	1.39M	-	1.75M	2.66M	471.08M	-	10.46M	3.91M	8.11M	-	2.62M	40.35M	44.26M	4.81M	8.65M	4.85M	10.54M	16.67M	72.21M	8.32M	5.88M	9.24M	25.43M	21.81M	-	7.04M	81.12M	2.62M	3.79M	6.24M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	157.74K	25.55M	1.00M	2.99M	2.94M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.88M	55.57M	1.62M	804.47K	3.30M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.14M	9.89M	11.84M	10.30M	8.62M
Operating Income	-5.04M	-4.33M	-3.63M	-17.95M	-7.06M	-9.29M	-8.06M	-6.61M	-4.27M	-4.06M	-5.65M	-4.87M	-4.54M	-3.71M	368.88M	-5.54M	2.19M	-1.71M	660.58K	-3.47M	-4.00M	28.80M	32.90M	-1.99M	1.10K	-2.94M	-1.44M	3.07M	42.87M	-2.11M	-4.64M	-1.31M	11.28M	1.08M	-	-2.26M	45.68M	-10.22M	-9.50M	-5.32M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.12M	45.82M	-10.08M	-9.35M	-5.17M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-570.41K	47.27M	-8.36M	-7.96M	-4.04M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-162.19K	11.79M	-1.99M	-2.53M	-589.43K
Net Income	-7.15M	-6.57M	-5.63M	-20.09M	-10.45M	-9.57M	-9.24M	-10.44M	-8.62M	-7.50M	-9.82M	-10.30M	-11.58M	-7.05M	388.05M	52.39M	1.63M	-3.16M	-1.21M	-4.50M	-8.90M	20.89M	24.19M	-812.11K	169.20K	-3.11M	-361.05K	2.04M	33.04M	-918.25K	-2.88M	-393.07K	10.28M	1.83M	-	-408.22K	35.48M	-6.37M	-5.43M	-3.45M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-0.12	-0.46	-0.15	-0.09	4.71	0.65	-0.02	-0.05	-0.03	-0.06	-0.11	0.26	0.31	-0.02	0.00	-0.04	-0.01	0.03	0.45	-0.01	-0.04	-0.01	0.14	0.03	0.02	-0.01	0.49	-0.09	-	-0.05
R&D Expense	2.81M	2.96M	2.43M	4.93M	2.54M	2.95M	6.07M	8.16M	6.36M	5.07M	2.47M	2.78M	3.01M	3.31M	3.72M	2.97M	4.00M	2.04M	3.34M	3.92M	3.15M	2.71M	2.07M	2.30M	2.26M	3.24M	3.55M	6.84M	5.73M	5.05M	5.12M	3.65M	3.05M	2.89M	3.02M	3.46M	4.40M	7.05M	-	3.95M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	14.99M	12.27M	477.05M	26.74M	124.96M	-	110.78M	139.92M	138.72M	94.57M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	10.43M	17.83M	31.29M	29.70M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	100.34M	122.09M	107.43M	64.87M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	57.64M	38.47M	37.45M	41.17M
Operating Income	-11.88M	-12.72M	-31.38M	-22.54M	-23.52M	-209.67M	-30.95M	-31.01M	-18.85M	355.10M	-2.32M	84.50M	-	42.70M	83.62M	69.98M	23.70M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	43.22M	84.16M	70.52M	24.26M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	44.13M	87.78M	76.07M	30.38M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	10.23M	19.71M	16.86M	7.10M
Net Income	-19.40M	-28.20M	29.10M	-14.06M	-17.18M	-265.46M	-39.45M	-39.70M	-36.24M	421.81M	-7.24M	56.34M	-	33.90M	68.07M	59.21M	23.28M
Diluted EPS	-0.52	-0.62	0.09	-0.27	-0.33	-4.97	-0.73	-0.69	-0.46	5.18	-0.15	0.71	-	0.46	0.95	0.82	0.32
R&D Expense	17.42M	22.66M	18.37M	18.21M	13.79M	10.71M	13.13M	19.71M	16.68M	13.02M	13.30M	10.94M	9.94M	22.53M	16.43M	12.31M	19.96M

Compounded Sales Growth

5 Years:	-5.13%
1 Year:	-11.30%

Compounded Profit Growth

5 Years:	-11.78%
1 Year:	-

Stock Price Performance

1 Year:	-11.53%
6 Months:	-11.09%
3 Months:	-18.23%
1 Month:	+3.31%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	27.03M	90.38M	105.84M	193.82M	160.73M	185.73M	160.98M	144.67M	203.44M	198.57M	149.83M	-	195.04M	254.35M	244.34M	219.47M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	185.79M	238.99M	231.04M	212.86M
Cash & Equivalents	2.32M	6.33M	6.33M	49.26M	32.02M	91.31M	99.71M	112.71M	28.70M	19.86M	100.65M	65.25M	117.89M	-	98.79M	150.15M	155.40M	154.97M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.27M	64.22M	49.56M	49.05M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45.41M	21.13M	21.17M	3.26M
Total Liabilities	-	-	14.96M	48.69M	77.59M	176.85M	407.23M	470.16M	448.40M	467.81M	100.53M	100.78M	20.04M	-	24.88M	57.49M	28.53M	20.65M
Current Liabilities	-	-	4.26M	6.92M	15.76M	12.19M	7.46M	7.33M	7.10M	6.81M	11.34M	91.74M	10.48M	-	21.52M	54.12M	25.33M	17.99M
Long Term Debt	-	-	-	0	3.96M	1.99M	0	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	528.17K	564.01K	546.82K	595.17K
Total Equity	1.36K	-12.91M	12.07M	40.77M	28.24M	16.98M	-246.50M	-284.43M	-287.42M	-323.14M	102.91M	97.78M	129.79M	-	170.16M	196.86M	215.80M	198.82M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72.68M	71.09M	71.40M	71.61M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-8.47M	-10.83M	25.57M	-20.22M	58.44M	14.18M	11.11M	-116.81M	-18.39M	68.87M	-18.20M	71.52M	-	41.61M	94.80M	48.76M	43.47M
Investing Cash Flow	-5.34M	-10.54M	14.76M	-1.94M	-857.34K	-3.46M	3.89M	1.19M	-100.12K	78.24M	-29.09K	-15.50K	-	0	-21.69K	-42.45K	-355.01K
Financing Cash Flow	25.99M	13.20M	2.59M	4.92M	1.71M	-2.31M	-2.00M	59.09M	-585.57K	-3.81M	-1.18M	-114.60M	-	-45.96M	-43.42M	-43.46M	-43.55M
Capital Expenditure	-340.73K	-549.94K	-237.02K	-588.24K	-857.34K	-28.05K	-108.95K	-23.93K	-100.12K	-102.26K	-29.09K	-	-50.62K	-	-21.69K	-42.45K	-355.01K
Free Cash Flow	-8.81M	-11.38M	25.34M	-20.81M	57.58M	14.15M	11.00M	-116.84M	-18.49M	68.77M	-18.23M	-	-	41.61M	94.78M	48.72M	43.12M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.35M	51.36M	5.25M	-433.85K
Share Buybacks	0	0	1.35M	0	-	-	0	0	84.00K	0	0	28.50M	26.02M	13.01M	11.07M	0	0
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	0	0	32.94M	32.14M	42.67M	43.12M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	90.6%	87.3%	77.4%	68.6%
Operating Margin %	-	-	-	-	-	-	-	-206.9%	-153.6%	74.4%	-8.7%	67.6%	-	38.5%	59.8%	50.4%	25.1%
Net Margin %	-	-	-	-	-	-	-	-264.9%	-295.3%	88.4%	-27.1%	45.1%	-	30.6%	48.6%	42.7%	24.6%
ROE %	150.2%	-233.6%	71.4%	-49.8%	-101.2%	107.7%	13.9%	13.8%	11.2%	409.9%	-7.4%	43.4%	-	19.9%	34.6%	27.4%	11.7%
ROCE %	-	-55.9%	-37.6%	-25.0%	-12.9%	-136.8%	-17.4%	-20.2%	-13.7%	184.8%	-2.2%	60.6%	-	24.6%	41.8%	32.0%	11.8%

Shareholding Pattern

Insiders

42.66%

Institutions

49.97%

Public Float

87.15%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	4.32%	3.49M	$16.35M
2	Dimensional Fund Advisors LP	3.34%	2.70M	$12.65M
3	AltraVue Capital, LLC	3.00%	2.43M	$11.38M
4	Vanguard Capital Management LLC	2.12%	1.71M	$8.02M
5	Arrowstreet Capital, Limited Partnership	1.89%	1.53M	$7.14M
6	American Century Companies Inc	1.63%	1.32M	$6.17M
7	Geode Capital Management, LLC	1.63%	1.32M	$6.16M
8	AQR Capital Management, LLC	1.51%	1.22M	$5.71M
9	State Street Corporation	1.25%	1.01M	$4.74M
10	First Wilshire Securities Management Inc	1.10%	890.50K	$4.17M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SIGA

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Headquarters	United States
Employees	49
Website	https://www.siga.com

SIGA Technologies, Inc. SIGA R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More